Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
18.45
+0.01 (+0.05%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024
October 27, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes
October 27, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Third Quarter 2021 Financial Results
October 27, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
October 26, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021
October 21, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Is This The Most Exciting Medical Breakthrough Of The Decade
October 19, 2021
FN Media Group Presents Oilprice.com Market Commentary London – October 19, 2021 – According to Google’s Health boss David Feinberg… over one billion people a day search Google for health concerns....
Via
FinancialNewsMedia
Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021
October 01, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN
September 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD
September 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims
September 28, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and Rimegepant
September 08, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...
August 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia
August 20, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis
July 28, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Second Quarter 2021 Financial Results
July 28, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Changes to Executive Management Team
July 21, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021
July 01, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Bioeq Announce Commercial Partnership for Biosimilar
June 28, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults
June 23, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States
June 22, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of Rosacea
June 16, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at 2021 American Headache Society (AHS) Annual Meeting
June 03, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva’s Longstanding Heritage in the Management of Migraine
June 03, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
The Companies Tackling A Global Health Crisis
May 20, 2021
Via
FinancialNewsMedia
Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets
May 17, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference
May 10, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
May 05, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States
May 04, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting
May 03, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States
April 29, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.